Emerging antibody-targeted therapy in leukemia and lymphoma: Current concepts and clinical implications

Anti-Cancer Drugs

Volumn 15, Issue 3, 2004, Pages 189-201

  Van De Loosdrecht, Arjan A ^a   Huijgens, Peter C ^a   Ossenkoppele, Gert J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antibodies; Immunotherapy; Leukemia; Lymphoma

Indexed keywords

ALEMTUZUMAB; ANTIBODY; ANTIGEN; CD16 ANTIGEN; CD32 ANTIGEN; CD40 ANTIGEN; CHLORAMBUCIL; COMPLEMENT; CYCLOPHOSPHAMIDE; CYTOKINE; EPRATUZUMAB; ETANERCEPT; ETOPOSIDE; FC RECEPTOR; FLUDARABINE; GALIXIMAB; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN; IMMUNOGLOBULIN IDIOTYPE; INFLIXIMAB; KEYHOLE LIMPET HEMOCYANIN; LUMILIXIMAB; NEUTRALIZING ANTIBODY; OBLIMERSEN; RITUXIMAB; SIPLIZUMAB; SU 5614; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VISILUZUMAB; Y2B8;

ACTIVE IMMUNIZATION; ANTIGEN ANTIBODY COMPLEX; ANTIGEN EXPRESSION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DENDRITIC CELL; DISEASE CLASSIFICATION; FOLLICULAR LYMPHOMA; GENE EXPRESSION; GENE TRANSFER; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; LARGE CELL LYMPHOMA; LEUKEMIA; LYMPHOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; STEM CELL TRANSPLANTATION;

ANIMALS; ANTIBODIES, NEOPLASM; CANCER VACCINES; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOTHERAPY; LEUKEMIA; LYMPHOMA;

EID: 1842607032     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200403000-00002     Document Type: Review

References (86)

1. Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoftini L, Marincola FM, et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going. J Natl Cancer Inst 2002; 94:805-818.
2. Steinman RM, Pope M. Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 2002; 109:1519-1526.
3. Brossart P, Wirths S, Brugger W, Kanz L. Dendritic cells in cancer vaccines. Exp Hematol 2001; 29:1247-1255.
4. Ossenkoppele GJ, Stam AGM, Westers TM, Gruijl TD de, Janssen JJWM, Loosdrecht AA van de, et al. Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells. Leukemia 2003; 17:1324-1426.
5. Westers TM, Stam ARM, Scheper RJ, Regelink JC, Niewint AWM, Schuurhuis GJ, et al. Rapid generation of antigen presenting cells from leukaemic blasts in acute myeloid leukaemia. Cancer Immunol Immunother 2003; 52:17-27.
6. Houtenbos I, Westers TM, Stam AGM, Gruijl TD de, Scheper RJ, Ossenkoppele GJ, et al. Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisation. Cancer Immunol Immunother 2003; 52:455-462.
7. Houtenbos I, Westers TM, Ossenkoppele GJ, Loosdrecht AA van de. Identification of CD 14 as a predictor for leukemia dendritic cell differentiation in acute myeloid leukemia. Leukemia 2003; 17:1683-1684.
8. Brandao JG, Scheper GJ, Lougheed SM, Curiel DT, Tillman BW, Gerritsen ER, et al. CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation. Vaccine 2003; 21:2268-2272.
9. Stam AGM, Santegoets SJAM, Westers TM, Sombroek CC, Janssen JJWM, Tillman BW, et al. CD40 targeted adenoviral GM-CSF gene transfer enhances and prolongs the maturation of human CML-derived dendritic cells upon cytokine deprivation. Br J Cancer 2003; 89:1162-1165.
10. Ruffini PA, Neelapu SS, Kwak LW, Biragyn A. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Haematologica 2002; 87:989-1001.
11. Chinn P, Braslawsky G, White C, Hanna N. Antibody therapy of non-Hodgkin's B-cell lymphoma. Cancer Immunol Immunother 2003; 52:257-280.
12. DiGaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003; 171:1581-1587.
13. Manches O, Lui G, Chaperot L, Gressin R, Molens J-P, Jacob M-C, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphoma. Blood 2003; 101:949-954.
14. Sorge NM van, Pol WL van der, Winkel JG van de. FcgammaR polymorphisms: implications for function disease susceptibility and immunotherapy. Tissue Antigens 2003; 61:189-202.
15. Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, et al. Anti-CD20 antibody (IDEC-C2B8, rutuximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement and caspases. Haematologica 2002; 87:33-43.
16. Harris NL, Jafe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. The WHO classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting, Arlie House, Virginia, November 1997. Histopathology 2000; 36:69-86.
17. Barrans SL, Carter I, Owen RG, Davies FE, Patmore RD, Haynes AP, et al. Germinal center phenotype and bcl-2 expression combined with the international prognostic index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002; 99:1136-1143.
18. Berge RL ten, Oudejans JJ, Ossenkoppele GJ, Meijer CJLM. Alk-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects - a review. J Pathol 2003; 200:4-15.
19. Staudt LM. Genomic medicine: molecular diagnosis of the hematologic cancers. N Engl J Med 2003; 348:1777-1785.
20. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International Scoring System for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2088-2097.
21. Vardiman JW, Harris NL, Brunning RD. The WHO classification of myeloid neoplasms. Blood 2002; 100:2292-2302.
22. Cesano A, Gayko U. CD22 as a target of passive immunotherapy. Semin Oncol 2003; 30:253-257.
23. Mavromatis B, Cheson BD. Monoclonal antibody therapy of chronic lymphocytic leukemia. J Clin Oncol 2003; 21:1874-1881.
24. Leonard JP, Link BK. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab) an anti-CD22 monoclonal antibody and HuiD10 (apolizumab). Semin Oncol 202; 29:81-86.
25. Younes A, Hariharan K, Allen RS, Leigh BR. Initial trials of anti-CD80 monoclonal antibody (galixumab) therapy for patients with relapsed or refractory follicular lymphoma. Clin Lymphoma 2003; 3:257-259.
26. Tutt AL, O'Brien L, Hussain A, Crowther GR, French RR, Glennie MJ. T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J Immunol 2002; 168:2720-2728.
27. Vanderheide RH, Dutcher JP, Anderson JE, Eckhardt SG, Stephans KF, Razvillas B, et al. Phase I study of recombinant CD40Ligand in cancer patients. J Clin Oncol 2001; 19:3280-3287.
28. Moreton P, Hillmen P. Alemtuzumab therapy in B-cell lymphoproliferative disorders. Semin Oncol 2003; 30:493-501.
29. Hale G, Slavin S, Goldman JM, Mackinnon S, Giralt S, Waldmann H. Alemtuzumab (Campath-1 H) for treatment of lymphoid malignancies in the age of nonmyeloabaltive conditioning. Bone Marrow Transplant 2002; 30:797-804.
30. Zhang Z, Zhang M, Ravetch JV, Goldman C, Waldmann TA. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. Blood 2003; 102:284-288.
31. Carpenter PA, Appelbaum FR, Corey L, Deeg J, Doney C, Gooley T, et al. A humanized non-FcR-binding anti-CD3 antibody visiluzumab for the treatment of steroid-refractory acute graft-versus-host disease. Blood 2002; 99:2712-2719.
32. Loffler A, Gruen M, Wuchter C, Schriever F, Kufer P, Dreier T, et al. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD 19/anti-CD3 single chain antibody construct. Leukemia 2003; 17:900-909.
33. Wahl AF, Klussman K, Thompson JD, Chen JH, Francisco LV, Risdon G, et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res 2002; 62:3736-3742.
34. Borchmann P, Treml JF, Hansen H, Gottstein C, Schnell R, Staak O, et al. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood 2003; 102:3737-3742.
35. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace JF, et al. CAA10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003; 102:1458-1465.
36. Schnell R, Borchman P, Staal JO, Schnidler J, Ghetie V, Vietta ES, et al. Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. Ann Oncol 2003; 14:7297-7236.
37. Van der Velden VHJ, Marvelde JG te, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger MS, et al. Targeting of the CD33-calicheamicin immunoconjugate mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001; 97:3197-3204.
38. Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjugate Chem 2002; 13:47-58.
39. Bross PF, Beitz J, Chen G, Hong XH, Duffy E, Kieffer L, et al. Gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7:1490-1496.
40. Feldman E, Kalaycio M, Weiner G, Frankel S, Schulman P, Schwartzberg L, et al. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia 2003; 17:314-318.
41. Pagel JM, Matthews DC, Appelbaum FR, Bernstein ID, Press OW. The use of radioimmunoconjugates in stem cell transplantation. Bone Marrow Transplant 2002; 29:807-816.
42. + acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein. Exp Hematol 2002; 30:1316-1323.
43. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial grwoth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427-434.
44. Frenando NH, Hurwitz HI. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol 2003; 30: 39-50.
45. Rosenfeld C, Bedell C. Pilot study of recombinant human soluble tumor necrosis factor receptor (TNFR:Fc) in patients with low risk myelodysplastic syndrome. Leuk Res 2002; 26:721-724.
46. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, et al. A validated decision model for targeting the anaemia of myelodysplastic syndromes with erythropoietin and granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003; 120:1037-1046.
47. Trail PA, King HD, Dubowchik GM. Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. Cancer Immunol Immunother 2003; 52:328-337.
48. Goldenberg DM. Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother 2003; 52:281-296.
49. Cheson BD. Radioimmunotherapy of non-Hodgkin lymphomas. Blood 2003; 101:391-998.
50. Kosmos C, Stamatopoulos K, Stavroyianni N, Tsavaris N, Papadaki T. Anti-CD20-based therapy of B-cell lymphoma: state of the art. Leukemia 2002; 16:2004-2015.
51. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-2833.
52. Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18:3135-3143.
53. Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97:101-106.
54. Hainsworth JD, Burris HA, Morrissey LH, Litchy S, Scullin DC, Bearden JD, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000; 95:3052-3056.
55. Hainsworth JD. Rituximab as first line maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trial. Semin Oncol 2002; 29:25-29.
56. Czuczman MS, Fallon A, Mohr A, Stewart C, Bernstein ZP, McCarthy P, et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol 2002; 29:36-40.
57. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17:268-276.
58. Leonard JP, Coleman M, Ketas JC, Chadbum A, Ely S, Furman RR, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 2003; 21:3051-3059.
59. Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, Fitzgerald DJ, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001; 345:241-247.
60. Lin TS, Lucas MS, Byrd JC. Rituximab in B-cell chronic lymphocytic leukemia. Semin Oncol 2003; 30:483-492.
61. Huhn D, Von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001; 98:1326-1331.
62. Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003; 21:1746-1751.
63. Lundin J, Kimby E, Bjorkholm M, Broliden PA, Celsing F, Hjalmar V, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1 H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100: 768-773.
64. Dimopoulos MA, Zervas C, Zomas A, Kiamouris C, Viniou NA, Grigoraki V, et al. Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol 2002; 20:2327-2333.
65. Dillman RO. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol 2002; 20:3545-3557.
66. Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 2003; 21:1263-1270.
67. Kamisky MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, et al. Pivotal study of iodine 1131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphoma. J Clin Oncol 2001; 19:3918-3928.
68. Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99:4336-4342.
69. Witzig TE, Gordon LI, Cabnillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:2453-2463.
70. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 1997; 19:389-397.
71. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235-242.
72. Mounier N, Brier J, Gisselbrecht C, Emile JF, Lederlin P, Sebban O, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2 associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101:4279-4284.
73. Pfreundschuh M, Truemper L, Kloess M, Schmidts R, Schmidtz N, Glass B, et al. 2-weekly vs 3-weekly CHOP with and without etoposide for patients >60 years of age with aggressive non-Hodgkin's lymphoma (NHL): results of the combined NHL-B-2 trial of the DSHNHL. Blood 2002; 100:774a.
74. Pfreundschuh M, Truemper L, Schmidts R, Kloess M, Schmidtz N, Glass B, et al. 2-weekly vs 3-weekly CHOP with and without etoposide for young patients with low-risk (low LDH) aggressive non-Hodgkin's lymphoma (NHL): results of the completed NHL-B-1 trial of the DSHNHL. Blood 2002; 100:92a.
75. Howard O, Gribben JG, Neuberg DS, Grossbard M, Poor C, Janicek MJ, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20:1288-1294.
76. Gianni AM, Magni M, Martelli M, DiNicola M, Carlo-Stell C, Pilotti S, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003; 102:749-755.
77. Pettengell R, Linch D. Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-Hodgkin's lymphoma. Br J Haematol 2003; 12:44-48.
78. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Löwenberg B, Dombret H, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse. J Clin Oncol 2001; 19:3244-3254.
79. Larson RA, Boogaerts M, Estey E, Karanes C, Stadtmauer EA, Sievers EL, et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukaemia in first relapse using mylotarg (gemtuzumab ozogamicin). Leukemia 2002; 16:1627-1636.
80. Linenberger ML, Hong T, Flowers D, Sievers EL, Gooley RA, Bennet JM, et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 2001; 98:944-988.
81. Cohen AD, Luger SM, Sickles C, Mangan PA, Porter DL, Schuster SJ, et al. Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplantation: efficacy and incidence of hepatic veno-occlusive disease. Bone Marrow Transplant 2002; 30:23-28.
82. Rajvanshi P, Schulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood 2002; 99:2310-2314.
83. Schmaltz C, Alpdogan O, Muriglan SJ, Kappel BJ, Rotolo JA, Ricchetti ET, et al. Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood 2003; 101:2440-2445.
84. Socie G, Mary JY, Lemann M, Daneshpouy M, Guardiola P, Meignin V, et al. G Prognostic value of apoptotic cells and infiltrating neutrophils in graft-versus-host disease of the gastrointestinal tract in humans: TNF and Fas expression. Blood 2004; 103:50-57.
85. Jacobson DA, Hallick J, Anders V, McMillan S, Morris L, Vogelsang GB. Infliximab for steroid-refractory acute GVHD: a case series. Am J Hematol 2003; 74:119-124.
86. Marty FM, Lee SJ, Fahey MM, Alyea EP, Soiffer RJ, Antin JH, et al. Infiximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-candida invasive fungal infections an allogeneic hematopoietic stem cell transplant recipients; a cohort study. Blood 2003; 102:2768-2776.